Research and Markets has announced the addition of the "Blincyto | Blinatumomab - Oncology Drug Report: 2014-2015 Analysis; 2016-2021 Expectations" report to their offering.

Blincyto: Expensive drug in a niche market is a comprehensive drug report about one of the most expensive drugs used in the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lympho-blastic leukaemia.

Blincyto is the breakthrough therapy drug approved by the USFDA and it falls under targeted therapy. It is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (Ph- R/R B-cell precursor ALL) and recently got USFDA approval for paediatric patients with Ph- R/R B-cell precursor ALL. We expect sales to see gradual and slow growth in the next few years as the drug is about to reach its maximum market share and has limited patient population.

The report gives basic information about the drug, covering all details from brand name, date of approvals, mechanism of action, molecular structure, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the drug, news about Blincyto, number of clinical trials (by year and by phase), and so on.

The report gives an analysis of the historical annual sales (from 2014-2015), historical quarter-ly sales (Q4-2014 to Q3-2016) and sales expectations (from 2016-2021). The analysis broadly indicates that the drug had a strong start but the growth is gradually tapering down.

Key Topics Covered:

1. Basic Information

2. Approval timeline infographic (2014-2016)

3. Regulatory approval details (US, Europe, Japan and RoW)

4. Historical annual sales analysis

5. Historical quarterly sales analysis (Q4-2014 to Q3-2016)

6. Historical cumulative sales (Q4-2014 to Q3-2016)

7. Q3-2016 update

8. Sales expectations (2016E-2021E)

9. Endpoint results for the Blincyto

10. Event tracker

11. Clinical trials of Blincyto (US)

12. News around Blincyto (including 6 press releases)

13. Methodology

14. Annexure

Companies Mentioned

  • Amgen
  • Astellas
  • Astrazeneca
  • Medimmune
  • Micromet

For more information about this report visit http://www.researchandmarkets.com/research/hs3mnn/blincyto